Sept. 12, 2016—Düsseldorf, Germany—Surefire Medical, Inc. today announced that the German Institute of Medical Documentation and Information (DIMDI) has issued a unique classification code (OPS) for the Surefire Infusion System, which will allow the governmental organization to track and measure the use of Surefire technology in German hospitals. The issuance of this code marks the first step to obtain a specific diagnosis-related group (DRG) code and the appropriate reimbursement for Surefire products in Germany.

The new OPS code – 8-83b.k – specifically calls out the use of a catheter-based infusion system with dynamic, expandable tip for selective embolization.

“This OPS code is a significant milestone for our commercialization efforts in Germany and to bringing our technology to market,” said James E. Chomas, CEO and President of Surefire Medical. “We look forward to making further investment in the geography and taking the required steps to gain the appropriate DRG and reimbursement.”

Early clinical evidence being presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Congress this year shows the results of a multi-center registry in which the use of the Surefire Precision Infusion System to deliver therapy in the treatment of primary liver cancer (hepatocellular carcinoma or HCC) was associated with a 68 percent complete tumor response and 92 percent objective tumor response.1


About Surefire Medical

Surefire Medical is inventing the future for cancer care with advanced treatment technology. We are pioneers, developing liver cancer infusion systems that overcome the limitations of traditional tools and delivery methods. Clinical discoveries combined with new, precise technology enable physicians to target tumors with superior accuracy, control and protection. Our Colorado-based team of physicians, engineers and researchers are united in a mission to progress cancer care and offer new hope to patients. Learn more:


1 J. Titano1, A. Arepally2, T. Fischbeck3, M. Katz3, A. Kim4, S.C. Rose5, A. Fischman61Icahn School of Medicine at Mount Sinai, Radiology, New York, NY/US, 2Piedmont Healthcare, Interventional Radiology, Atlanta, GA/US, 3Keck School of Medicine of USC, Interventional Radiology, Los Angeles/US, 4MedStar Georgetown, Abstract ID 70503, “Transarterial chemoembolization utilizing an expandable-tip antireflux microcatheter: a multi-institution study of safety, feasibility, and early outcomes”, presented at the CIRSE 2016 Congress.


Clinical Data Shows Surefire Technology Achieved 79% Objective Response versus 37% Using a Standard Microcatheter in Treating Primary Liver Cancer. Study presented at SIR 2017 Annual Scientific Meeting.